Obesity affects almost half of adults in the United States.
In the United States, over 40% of people are affected by obesity and unless the obesity stems from a pre-existing condition, Medicare is prohibited from covering drugs strictly for weight loss due to a Medicare Part D law passed in 2003.
However, 76% of adults in the United States are in favor of Medicare coverage for weight management, according to the National Poll for Healthy Aging, published by the University of Michigan.
Researchers asked roughly 2,700 adults ages 50-80 about their weight, how they managed it and their views on Medicare coverage of weight loss drugs such as Wegovy and Zepbound, which have experienced a 300% increase in demand, CNBC reports.
Almost three-quarters of respondents reported that they had been overweight at some point in their lives. In addition, 92% had tried at least one method to lose weight, with exercise being the most common choice at 89%. Of the people who had never taken a drug strictly for weight loss, 59% said they would be interested in taking one in the future.
“Expanding access to a range of weight management treatments can lead to improvements in health and potentially lower costs,” the authors write. “Many weight loss medications are very expensive, resulting in high potential out-of-pocket costs.”
For example, without coverage, a 30-day supply of Ozempic currently costs around $950, according to GoodRx.
Additional weight loss strategies participants were in favor of covering were dietician sessions (83%), weight loss surgery (73), and gym memberships (65%).
The results of the University of Michigan study were published Dec. 2023. The research was conducted in July and August.
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
A Motor Neuron Mystery Points to New Potential SMA Treatment Targets
December 20th 2024Some muscles are resistant to the loss of motor neurons seen in patients with spinal muscular atrophy, and new research has discovered that even in muscles that appeared resistant to SMA, subtle changes had occurred at the cellular level.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen